Celemics

331920 · KOSDAQ · Health Care · SMALL CAP

Net income turned to a loss.

Celemics reported consolidated results for FY2025: revenue of US$4.09M (−12.3% year on year), an operating loss of US$2.23M and a net loss of US$2.73M (from a profit a year earlier).

Earnings(Change of 30% or more in revenue or profit/loss structure (15% for large companies))· FILED 2026-02-19· RCEPT 20260219900530

US$4.09MRevenue
−12.3%Revenue vs a year earlier
−US$2.23MOperating profit

Converted at 1 USD ≈ ₩1,440.16 (filing-date rate, 2026-02-19 close)

What happened

Celemics reported consolidated results for FY2025: revenue of US$4.09M (−12.3% year on year), an operating loss of US$2.23M and a net loss of US$2.73M (from a profit a year earlier).

Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.

RevenueUS$4.09M
Revenue vs a year earlier−12.3%
Operating profit−US$2.23M
Net income−US$2.73M
PeriodFY2025 (consolidated)
Filed2026-02-19, Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SourceDART rcept 20260219900530 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-19 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.